Literature DB >> 26872636

Psychometric validation of a patient-reported measure of physical functioning in sporadic inclusion body myositis.

Valerie Williams1, Theresa Coles2, Ari Gnanasakthy2, Carla Demuro2, Stuart Yarr2, Nicole Williams2, Linda Lowes3, Lindsay Alfano3, Brian Tseng4.   

Abstract

INTRODUCTION: To assess self-reported physical functioning in patients with sporadic inclusion body myositis (sIBM), the sIBM Physical Functioning Assessment (sIFA) was developed. This research establishes the validity, reliability, and responsiveness of the sIFA in patients with sIBM.
METHODS: Data from 3 small, noninterventional, observational studies were analyzed. Several measures of physical function were included to assess validity. Reliability (Cronbach alpha, test-retest intraclass correlations), construct validity (correlations, analyses of variance), and responsiveness (effect size estimates) were evaluated.
RESULTS: Cronbach alphas (range = 0.86-0.91) and test-retest reliability (0.91) were highly satisfactory. Correlations with other measures provided evidence of convergent validity. sIBM patients able to walk without assistive devices scored significantly better on the sIFA (means = 36.0-47.05) than those who required power mobility or wheelchairs (means = 54.9-71.5), demonstrating the discriminating ability of the sIFA. Effect size estimates of responsiveness suggested mild functional progression.
CONCLUSIONS: Psychometric analyses of the sIFA demonstrate satisfactory reliability, validity, and responsiveness. Muscle Nerve 54: 658-665, 2016.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  patient-reported outcomes; physical functioning; psychometric evaluation; sporadic inclusion body myositis; validation

Mesh:

Year:  2016        PMID: 26872636     DOI: 10.1002/mus.25080

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  3 in total

Review 1.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

2.  Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.

Authors:  Anthony A Amato; Michael G Hanna; Pedro M Machado; Umesh A Badrising; Hector Chinoy; Olivier Benveniste; Ananda Krishna Karanam; Min Wu; László B Tankó; Agnes Annette Schubert-Tennigkeit; Dimitris A Papanicolaou; Thomas E Lloyd; Merrilee Needham; Christina Liang; Katrina A Reardon; Marianne de Visser; Dana P Ascherman; Richard J Barohn; Mazen M Dimachkie; James A L Miller; John T Kissel; Björn Oskarsson; Nanette C Joyce; Peter Van den Bergh; Jonathan Baets; Jan L De Bleecker; Chafic Karam; William S David; Massimiliano Mirabella; Sharon P Nations; Hans H Jung; Elena Pegoraro; Lorenzo Maggi; Carmelo Rodolico; Massimiliano Filosto; Aziz I Shaibani; Kumaraswamy Sivakumar; Namita A Goyal; Madoka Mori-Yoshimura; Satoshi Yamashita; Naoki Suzuki; Masashi Aoki; Masahisa Katsuno; Hirokazu Morihata; Kenya Murata; Hiroyuki Nodera; Ichizo Nishino; Carla D Romano; Valerie S L Williams; John Vissing; Lixin Zhang Auberson
Journal:  Neurology       Date:  2021-02-17       Impact factor: 9.910

3.  Development and validation of a Bayesian survival model for inclusion body myositis.

Authors:  Gorana Capkun; Jens Schmidt; Shubhro Ghosh; Harsh Sharma; Thomas Obadia; Ana de Vera; Valery Risson; Billy Amzal
Journal:  Theor Biol Med Model       Date:  2019-11-07       Impact factor: 2.432

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.